Paper Details

  1. Home
  2. Paper Details

Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.

Author: CoreyG Ralph, DasAnita F, De AndaCarisa, FangEdward, LodiseThomas P, ProkocimerPhilippe, ShorrAndrew F

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tedizolid, a novel oxazolidinone effective against various Gram-positive pathogens, was evaluated in two phase 3 trials for acute bacterial skin and skin structure infections. In a pooled analysis, tedizolid demonstrated noninferior efficacy compared to linezolid, with a favorable tolerability profile. Tedizolid led to fewer cases of low platelet counts and gastrointestinal side effects than linezolid, aligning well with antimicrobial stewardship principles.
Paper Details　
Original Abstract of the Article :
Tedizolid, a novel oxazolidinone with activity against a wide range of Gram-positive pathogens, was evaluated in two noninferiority phase 3 acute bacterial skin and skin structure infection trials. The data from individual trials showed its noninferior efficacy compared to that of linezolid and a fa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335893/

データ提供：米国国立医学図書館（NLM）

Tedizolid and Linezolid: A Head-to-Head Comparison for Skin Infections

Skin infections, often caused by bacteria, can be as uncomfortable and challenging to treat as navigating a desert with a persistent rash. This research compares two antibiotics, tedizolid and linezolid, for the treatment of acute bacterial skin and skin structure infections. The study examines the efficacy and safety of these antibiotics, seeking to find the most effective weapon in the fight against these infections.

Tedizolid: A New Hope for Skin Infections

The research suggests that tedizolid is a safe and effective treatment option for acute bacterial skin and skin structure infections. This finding offers hope for improved outcomes for patients, much like finding a reliable source of water in a dry and arid desert. The study highlights the potential of tedizolid as an alternative to linezolid, providing a wider range of therapeutic choices for treating these infections.

Treating Skin Infections: Finding the Right Path to Recovery

This research emphasizes the importance of finding the right treatment for skin infections. It's a journey of discovery, much like a desert explorer seeking a path to a hidden oasis. The study provides valuable insights into the efficacy of different antibiotics, offering hope for a faster and more comfortable recovery.

Dr.Camel's Conclusion

This research represents a significant advancement in the treatment of skin infections. It's a journey of discovery, much like finding a hidden oasis in a vast and challenging desert. I, Dr. Camel, believe that this study will inspire continued research and development of new antibiotics, offering hope for a future where skin infections are effectively treated and managed.
Date :
  1. Date Completed 2015-10-07
  2. Date Revised 2018-12-24
Further Info :

Pubmed ID

25421472

DOI: Digital Object Identifier

PMC4335893

Related Literature

Article Analysis
・Side Effects of tedizolid
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.